vs
Side-by-side financial comparison of Emerald Holding, Inc. (EEX) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $132.7M, roughly 1.3× Emerald Holding, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -22.8%, a 24.4% gap on every dollar of revenue. On growth, Emerald Holding, Inc. posted the faster year-over-year revenue change (24.3% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -0.3%).
TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
EEX vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $132.7M | $177.4M |
| Net Profit | $-30.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -11.8% | 3.9% |
| Net Margin | -22.8% | 1.6% |
| Revenue YoY | 24.3% | 5.0% |
| Net Profit YoY | -692.2% | — |
| EPS (diluted) | $-0.15 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $132.7M | $196.9M | ||
| Q3 25 | $77.5M | $179.5M | ||
| Q2 25 | $105.5M | $181.1M | ||
| Q1 25 | $147.7M | $168.9M | ||
| Q4 24 | $106.8M | $187.3M | ||
| Q3 24 | $72.6M | $168.6M | ||
| Q2 24 | $86.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-30.2M | — | ||
| Q3 25 | $-14.4M | $5.4M | ||
| Q2 25 | $-1.4M | $-4.8M | ||
| Q1 25 | $15.3M | $4.8M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $-11.1M | $-143.5M | ||
| Q2 24 | $-2.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -11.8% | 1.2% | ||
| Q3 25 | -10.1% | 3.5% | ||
| Q2 25 | 9.7% | 4.7% | ||
| Q1 25 | 24.2% | 1.2% | ||
| Q4 24 | 19.5% | 13.2% | ||
| Q3 24 | -6.5% | -82.8% | ||
| Q2 24 | 7.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -22.8% | — | ||
| Q3 25 | -18.6% | 3.0% | ||
| Q2 25 | -1.3% | -2.7% | ||
| Q1 25 | 10.4% | 2.8% | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | -15.3% | -85.1% | ||
| Q2 24 | -3.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.15 | $0.05 | ||
| Q3 25 | $-0.07 | $0.12 | ||
| Q2 25 | $-0.01 | $-0.11 | ||
| Q1 25 | $0.08 | $0.10 | ||
| Q4 24 | $0.01 | $0.38 | ||
| Q3 24 | $-0.05 | $-3.11 | ||
| Q2 24 | $-0.03 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $100.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.8M | $653.9M |
| Total Assets | $1.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $100.9M | $238.4M | ||
| Q3 25 | $95.4M | $246.3M | ||
| Q2 25 | $156.4M | $445.9M | ||
| Q1 25 | $276.8M | $493.6M | ||
| Q4 24 | $194.8M | $484.6M | ||
| Q3 24 | $188.9M | $453.8M | ||
| Q2 24 | $193.2M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $338.8M | $693.1M | ||
| Q3 25 | $369.5M | $727.2M | ||
| Q2 25 | $389.4M | $757.8M | ||
| Q1 25 | $392.1M | $798.5M | ||
| Q4 24 | $385.9M | $778.3M | ||
| Q3 24 | $391.1M | $749.6M | ||
| Q2 24 | $407.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | — |
| Free Cash FlowOCF − Capex | $11.7M | — |
| FCF MarginFCF / Revenue | 8.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $12.3M | $43.7M | ||
| Q3 25 | $1.8M | $60.8M | ||
| Q2 25 | $15.9M | $12.0M | ||
| Q1 25 | $12.6M | $35.5M | ||
| Q4 24 | $20.6M | $33.1M | ||
| Q3 24 | $9.1M | $53.9M | ||
| Q2 24 | $9.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $11.7M | $43.5M | ||
| Q3 25 | $1.5M | $57.0M | ||
| Q2 25 | $15.8M | $9.3M | ||
| Q1 25 | $12.4M | $26.9M | ||
| Q4 24 | $19.9M | $31.0M | ||
| Q3 24 | $9.0M | $49.8M | ||
| Q2 24 | $9.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 8.8% | 22.1% | ||
| Q3 25 | 1.9% | 31.7% | ||
| Q2 25 | 15.0% | 5.1% | ||
| Q1 25 | 8.4% | 15.9% | ||
| Q4 24 | 18.6% | 16.6% | ||
| Q3 24 | 12.4% | 29.6% | ||
| Q2 24 | 11.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 0.4% | 2.2% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 0.7% | 1.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.82× | 7.37× | ||
| Q4 24 | 4.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EEX
| Connections Segment | $121.9M | 92% |
| Commerce Segment | $5.5M | 4% |
| Content | $5.3M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
